P
ABVX

&Partners’s Abivax ABVX Stock Holding History

&Partners’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,854
Closed -$206K – 2510
2026
Q1 		$206K Sell
1,854
-360
-16% -$42.6K ﹤0.01% 2234
2025
Q4 		$299K Buy
+2,214
New +$242K ﹤0.01% 1915

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

&Partners's ABVX Position: Q2 2026 in Review

&Partners sold out of Abivax (ABVX) in Q2 2026, closing a stake of 1,854 shares — an estimated $206K sold.

&Partners first reported a position in ABVX in Q4 2025 and held it in 2 quarters. The position peaked at $299K in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • &Partners reported no remaining Abivax position as of Q2 2026 after selling out during the quarter.
  • &Partners sold 1,854 Abivax shares in Q2 2026, an estimated $206K.
  • &Partners first reported a position in Abivax in Q4 2025 and held it in 2 quarters.
  • &Partners's Abivax position peaked at $299K in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.